Research focuses on blood-borne biomarkers for the development of targeted cancer therapies.

Cancer Research Technology (CRT) and The University of Manchester entered into an agreement with AstraZeneca to establish a clinical pharmacology biomarker research and discovery collaboration.

Within the collaboration, two clinical pharmacology research fellowships will be jointly funded by Cancer Research UK and AstraZeneca, strengthening existing collaborative links between AstraZeneca, CRT, and the Cancer Research UK core-funded Paterson Institute for Cancer Research. The clinical research fellowships aim to identify and validate circulating biomarkers for use in conjunction with targeted cancer therapies.

Within the three-year fellowship programs, clinical research fellows will receive training in translational research and Phase I clinical trials from academic, clinical, and industry perspectives at the Paterson Institute for Cancer Research, the Christie Hospital, and AstraZeneca. This collaboration serves as a pilot for an anticipated rolling joint Cancer Research UK/AstraZeneca Clinical Pharmacology Programme.

This collaboration focuses on the investigation of blood-borne biomarkers. As blood samples can be taken much more frequently and easily than tissue biopsies, such circulating biomarkers are particularly valuable for the development of targeted cancer therapies.

Previous articleArtemis and Merck & Co to Generate Genetically Engineered In-Vivo RNAi Mouse Models
Next articleGene Sequencing Center to Receive $156 Million